- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 473/32 - Nitrogen atom
Patent holdings for IPC class C07D 473/32
Total number of patents in this class: 249
10-year publication summary
15
|
16
|
15
|
15
|
9
|
22
|
11
|
19
|
10
|
9
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Signal Pharmaceuticals, LLC | 181 |
20 |
Boehringer Ingelheim International GmbH | 4642 |
8 |
Celgene Corporation | 1395 |
8 |
Chengdu Baiyu Pharmaceutical Co., Ltd. | 68 |
6 |
Board of Regents, The University of Texas System | 5849 |
5 |
Takeda Pharmaceutical Company Limited | 2705 |
5 |
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | 191 |
5 |
Neupharma, Inc. | 72 |
5 |
S*BIO Pte Ltd. | 24 |
5 |
AstraZeneca AB | 2908 |
4 |
Cancer Research Technology Limited | 527 |
4 |
Incyte Holdings Corporation | 665 |
4 |
Pharmacopeia, Inc. | 14 |
4 |
Research Triangle Institute | 406 |
4 |
Kangbaida (Sichuan) Biotechnology Co., Ltd. | 21 |
4 |
F. Hoffmann-La Roche AG | 7941 |
3 |
The Regents of the University of California | 20059 |
3 |
Wyeth LLC | 657 |
3 |
Purdue Research Foundation | 3664 |
3 |
Ildong Pharmaceutical Co., Ltd. | 91 |
3 |
Other owners | 143 |